Cancer Advisor

Summary Background: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited effective therapies and poor survival, especially in stage 4 disease. Repurposing antiparasitic agents such as fenbendazole and ivermectin has garnered interest due to their demonstrated anti-cancer properties in preclinical studies. Methods: We reviewed and synthesized 35 detailed case reports from 2022 to 2026 documenting the clinical use of fenbendazole and ivermectin, alone or in combination with standard therapies, in patients with advanced pancreatic cancer. Tumor markers, imaging outcomes, and clinical responses were analyzed alongside mechanistic literature. Results: Across cases, patients exhibited marked reductions in CA19-9 tumor markers (often >70%), significant tumor shrinkage on imaging, and improved clinical status. Responses were observed even in chemotherapy-resistant and metastatic disease. Mechanistic studies support multiple anti-cancer effects of...

From “Undruggable” to One of the Most Important Targets in Cancer Medicine For decades, KRAS mutations were considered one of the most challenging problems in oncology. The protein was structurally smooth, biologically complex, and notoriously resistant to drug binding. It became known in medical literature as “undruggable.” That narrative changed dramatically in the early 2020s. Today, KRAS is no longer a scientific dead end—it is one of the most actively targeted oncogenic drivers in modern precision medicine. Multiple generations of KRAS inhibitors now exist, and treatment strategies are evolving from single-mutation targeting toward pan-RAS pathway control and combination therapy systems . However, despite major breakthroughs, KRAS-driven cancers remain difficult to cure. The reason is not a lack of drugs—but the adaptability of cancer biology itself. This article provides a complete 2026 update on KRAS inhibitors, including mechanisms, approved therapies, emerging drugs, resistanc...

Pancreatic cancer has long been one of the most feared diagnoses in oncology—aggressive, late-detected, and historically resistant to treatment. But 2026 marks a potential turning point. A recent report by The Washington Post highlights early but meaningful survival improvements in clinical trials, signaling a new era for one of the deadliest cancers. A convergence of  KRAS-targeted therapies, immunotherapy, personalized vaccines, and metabolic strategies—including repurposed drugs like Ivermectin and Mebendazole—is reshaping the treatment landscape.  Reports highlighted by The Washington Post and emerging clinical trial data suggest that pancreatic cancer may be entering its first true era of therapeutic progress. This pillar page delivers a  deep, evidence-based, clinically grounded analysis  of: What’s actually changed in 2026 The role of KRAS inhibitors and immunotherapy The rise of targeted metabolic therapy Where repurposed drugs fit (and where they don’t) Sur...

A b s t r a c t B a c k g r o u n d : Stage 4 colorectal cancer (CRC) has poor prognosis, driven by cancer stem cells (CSCs). Repurposed drugs (ivermectin, mebendazole) with supplements and a ketogenic diet show promise in targeting CSC pathways. O b j e c t i v e : To evaluate   integrative multimodal protocol  (including high-dose oral ivermectin (1 mg/kg 3x/week, escalating to 1.5 mg/kg for non-responders), mebendazole (100 mg twice daily), IV vitamin C, oral vitamin D, oral zinc, ketogenic diet, and intermittent fasting) vs. FOLFOX or placebo in virtual patients with stage 4 CRC. M e t h o d s : An in silico RCT simulated 1,000 patients randomized to three arms. Molecular docking (AutoDock Vina), molecular dynamics (GROMACS), and pharmacokinetic/pharmacodynamic (PK/PD) modeling (Simcyp) assessed drug-target interactions. Primary endpoint: OS at 12 months; secondary end...